These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 28069289)

  • 41. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 45. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors].
    Noël N; Couteau J; Maillet G; Gobet F; d'Aloisio F; Minier C; Pfister C
    Prog Urol; 2013 Jan; 23(1):29-35. PubMed ID: 23287481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
    Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
    Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
    Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer.
    Blanca A; Sanchez-Gonzalez A; Requena MJ; Carrasco-Valiente J; Gomez-Gomez E; Cheng L; Cimadamore A; Montironi R; Lopez-Beltran A
    APMIS; 2019 Aug; 127(8):545-553. PubMed ID: 31231851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.
    Jungels C; Martinez Chanza N; Albisinni S; Mercier M; d'Haene N; Rorive S; Roumeguère T
    Prog Urol; 2018 May; 28(6):344-350. PubMed ID: 29673906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
    Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
    Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
    Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
    Yang Z; Zhang R; Ge Y; Qin X; Kang X; Wang Y; Zhang X; Song C; Quan X; Wang H; Chen H; Li C
    EBioMedicine; 2018 Sep; 35():198-203. PubMed ID: 29941343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.